Coronavirus Update: AstraZeneca To Develop Oxford’s Vaccine, Adaptive Trial Delivers Remdesivir's Good News

More Details From China's Negative Results In Lancet

 
• By Scrip Team

AstraZeneca is to develop and distribute Oxford's COVID-19 vaccine candidate in collaboration with Vaccitech. Its developers believe it could be available as early as September.

AZ_Courtyard
AstraZeneca's new HQ is in Cambridge, but has a longstanding basic research relationship with the University of Oxford

More from COVID-19

More from Scrip